Niagen Bioscience (NAGE) Competitors

Niagen Bioscience (NASDAQ:NAGE) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Which has more volatility and risk, NAGE or ADMA?

Niagen Bioscience has a beta of 2.14, suggesting that its share price is 114% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Do analysts rate NAGE or ADMA?

Niagen Bioscience presently has a consensus price target of $19.50, indicating a potential upside of 62.91%. ADMA Biologics has a consensus price target of $27.67, indicating a potential upside of 55.34%. Given Niagen Bioscience's higher possible upside, research analysts plainly believe Niagen Bioscience is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Does the media prefer NAGE or ADMA?

In the previous week, ADMA Biologics had 4 more articles in the media than Niagen Bioscience. MarketBeat recorded 5 mentions for ADMA Biologics and 1 mentions for Niagen Bioscience. ADMA Biologics' average media sentiment score of 1.27 beat Niagen Bioscience's score of 0.17 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Niagen Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADMA Biologics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher valuation and earnings, NAGE or ADMA?

ADMA Biologics has higher revenue and earnings than Niagen Bioscience. ADMA Biologics is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$99.60M	9.47	$8.55M	$0.17	70.41
ADMA Biologics	$426.45M	9.97	$197.67M	$0.85	20.95

Do insiders & institutionals have more ownership in NAGE or ADMA?

15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 9.4% of Niagen Bioscience shares are owned by insiders. Comparatively, 3.7% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Is NAGE or ADMA more profitable?

ADMA Biologics has a net margin of 45.01% compared to Niagen Bioscience's net margin of 13.07%. ADMA Biologics' return on equity of 47.16% beat Niagen Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	13.07%	19.06%	12.20%
ADMA Biologics	45.01%	47.16%	30.51%

Summary

ADMA Biologics beats Niagen Bioscience on 12 of the 16 factors compared between the two stocks.